<SEC-DOCUMENT>0001078782-20-000010.txt : 20200110
<SEC-HEADER>0001078782-20-000010.hdr.sgml : 20200110
<ACCEPTANCE-DATETIME>20200110161045
ACCESSION NUMBER:		0001078782-20-000010
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200108
FILED AS OF DATE:		20200110
DATE AS OF CHANGE:		20200110

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			AEON Biopharma, Inc.
		CENTRAL INDEX KEY:			0001622667
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38381
		FILM NUMBER:		20521174

	BUSINESS ADDRESS:	
		STREET 1:		4040 MACARTHUR BOULEVARD
		STREET 2:		SUITE 310
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		949-284-4555

	MAIL ADDRESS:	
		STREET 1:		4040 MACARTHUR BOULEVARD
		STREET 2:		SUITE 310
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660

	FORMER NAME:	
		FORMER CONFORMED NAME:	Alphaeon Corp
		DATE OF NAME CHANGE:	20141017

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>primary_doc.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2020-01-08</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0001570562</issuerCik>
        <issuerName>Evolus, Inc.</issuerName>
        <issuerTradingSymbol>EOLS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001622667</rptOwnerCik>
            <rptOwnerName>AEON Biopharma, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>4040 MACARTHUR BOULEVARD</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE 310</rptOwnerStreet2>
            <rptOwnerCity>NEWPORT BEACH</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92660</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>1</isOther>
            <otherText>Former 10% Owner</otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2020-01-08</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>8662346</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Pursuant to a Contribution Agreement dated January 8, 2020, by and between the Reporting Person (formerly known as Alphaeon Corporation) and Alphaeon 1 LLC (&quot;Alphaeon&quot;), on January 8, 2020, the Reporting Person contributed 8,662,346 shares of the Issuer to Alphaeon (the &quot;Contribution&quot;).  The shares of the Issuer contributed to Alphaeon are deemed &quot;restricted securities&quot; under Rule 144 promulgated under the Securities Act of 1933, as amended.  At the time of the Contribution, Alphaeon was a wholly-owned subsidiary of the Reporting Person.  Immediately after the Contribution, the Reporting Person distributed out all of the membership interests of Alphaeon to its stockholders.  The Reporting Person is filing this exit Form 4 to report that it is no longer a beneficial owner of the Issuer's securities.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Vik Malik, Acting President of AEON BIOPHARMA, INC</signatureName>
        <signatureDate>2020-01-08</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
